References
Alexander J, Dainiak N, Berger HJ, etal. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.N Engl J Med 1979; 300: 278–283.
Dardir MH, Ferrans VJ, Mikhael SY, etal. Cardiac morphologic and functional changes induced by epirubicin chemotherapy.J Clin Oncol 1989; 7: 947–958.
Druck MM, Gulenchyn KY, Evans WK, etal. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.Cancer 1984; 53: 1667–1674.
Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycininduced free radical formation in the perfused rat heart: implications for cardiotoxicity. Cancer Res 1988; 48: 4766–4769.
Lee BH, Goodenday LS, Muswick GJ, etal. Alterations in left ventricular diastolic function with doxorubicin therapy.J Ain Coll Cardiol 1987; 9: 184–188.
Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity: hemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease.Br Heart J 1986; 55: 274–282.
Severs NJ, Twist VW, Powell T. Acute effects of adriamycin on the macromolecular organization of the cardiac muscle cell plasma membrane.Cardioscience 1991; 2: 35–45.
Lipshultz SE, Colan SD, Gelber RD, etal. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukaemia in childhood.N Engl J Med 1991; 324: 808–815.
Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients.Med Pediatr Oncol 1995; 24: 352–361.
Strashun A. Adriamycin, congestive cardiomyopathy, and metaiodobenzylguanidine [editorial].J Nucl Med 1992; 33: 215–222.
Schwartz RG, McKenzie MB, Alexander J, etal. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy.Am J Med 1987; 82: 1109–1118.
Van Hoff DD, Layard MW, Basa P, etal.Risk factors for doxorubicin-induced congestive heart failure.Ann Intern Med 1979; 91: 710–717.
Speyer JL, Green MD, Kramer E, etal. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin induced cardiac toxicity in women with advanced breast cancer.N Engl J Med 1988; 319: 745–752.
Legha SS, Benjamin RS, Mackay B, etal. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.Ann Intern Med 1982; 96: 133–139.
Lokich J, Bothe A, Zipoli T, etal. Constant infusion schedule for adriamycin: a phase 1-II clinical trial of a 30 day schedule by ambulatory pump delivery system. J Clin Oncol 1983; 1: 24–28
Bacci G, Picci P, Ferrari S, etal. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.J Chemother 1993; 5: 237–246.
Ewer MS, Ali MK, Mackay B, etal. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin.J Clin Oncol 1984; 2: 112–117.
Lipshultz SE, Sanders SP, Goorin AM, etal. Monitoring for anthracycline cardiotoxicity.Pediatrics 1994; 93: 433–437.
Blatt J, DeLaat C, Fricker FJ, Janosky JE. Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.Pediatr Hematol Oncol 1995; 12: 61–66.
Mameghan H, Fischer RJ, O'Gorman-Hughes D, etal. Swing's sarcoma: long term follow up in 49 patients treated from 1967 to 1989.Int J Radiat Oncol Biol Phys 1993; 25: 431–438.
Nakada S, Ogawa S. Hirayama T. Noninvasive evaluation of chronic cumulative and acute cardiotoxicity induced by anthracycline in children with acute leukemia. Assessment of mainly left ventricular contractile state by M mode echocardiography.Nippon Ika Daigaku Zasshi 1994: 61: 209–219.
Aviles A, Arevila N, Diaz Maqueo JC, etal. Late cardiac toxicity of doxorubicin, epirubicin and mitoxantrone therapy for Hodgkin's disesae in adults.Leuk Lymphoma 1993; 11: 275–279.
GanzWI, Sridar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.Am J Clin Oncol 1993; 16: 109–112.
Palmeri ST, Bonow RO, Myers CE, etal. Prospective evaluation of doxorubicin by rest and exercise radionuclide angiography.Am J Cardiol 1986; 58: 607–613.
Steinherz LJ, Graham T, Hurwitz R, etal. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group.Pediatrics 1992; 89: 942–949.
Stoddard MF, Seeger J, Liddell NE, etal. Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans.J Am Coll Cardiol 1992; 20: 62–69.
Cittadini A, Fazio S, D'Ascia C, etal. Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study.Eur Heart J 1991; 12: 1000–1005.
Estorch M, Carrió I, Bernd L, etal. Indium- 111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.J Nucl Med 1990; 12: 1965–1970.
Carrió I, EstorchM, Berná L, etal. Assessment of anthracycline-induced myocardial damage by quantitative indium-111 myosin-specific monoclonal antibody studies.Eur J Nucl Med 1991; 18: 806–812.
Carrió I, Lopez-Pousa A, Estorch M, etal. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium111-antimyosin monoclonal antibody studies.J Nucl Med 1993; 34: 1503–1507.
Valdés-Olmos R, Ten Bokkel Huinink WW Ten Hoeve RF, etal. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracyclineassociated left ventricular dysfunction.Ann Oncol 1994; 5: 617–627.
Narula J, Strauss HW Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence.J Nucl Med 1993; 9: 1507–1509.
Praet M, Ruysschaert JM. In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives.Biochim Biophys Acta 1993; 1149: 79–85.
Wakasugi S, Wada A, Hasegawa Y, Naano S, Shibata N. Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine- 125-metaiodobenzylguanidine.J Nucl Med 1992; 33: 208–214.
Wakasugi S, Fischman AJ, Babich JW etal. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy.J Nucl Med 1993; 34: 1282–1286.
Valdés-Olmos S, ten Bokkel Huinink WW, Greve JC, etal. 1123 MIBG and serial radionuclide angiocardiography in doxo rubicin-related cardiotoxicity.Clin Nucl Med 1992; 17: 163–167.
Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, etal. Assessment of anthracycline-related myocardial adrenergic derangement by 1231-MIBG scintigraphy.Ear J Cancer 1995; 31A: 26–31.
Carrió I, Estorch M, Bernd L, etal.111In-antimyosin and123I-MIBG studies in the early assessment of doxorubicin cardiotoxicity.J Nucl Med 1995; 36: 2044–2049.
Miyagawa M, Tanada S, Hamamoto K. Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.Eur J Nucl Med 1991; 18: 332–338.
Piwnica-Worms D, Chin ML, Kronauge IF. Detection of adriamycin-induced cardiotoxicity in cultured heart cells with technetium 99m-sestamibi.Cancer Chemother Pharmacol 1993;32:385–391.
Takeishi Y, Sukekawa H, Sakurai T, etal. Noninvasive identification of anthracycline cardiotoxicity: comparison of 1231_ MIBG and123I-BMIPP imaging.Ann Nucl Med 1994; 8: 177–182.
Gianni L, Munzone E, Capri G, etal. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer. High antitumor efficacy and cardiac effects in a dose and sequence-finding study.J Clin Oncol 1996, in press.
Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.Ann Intern Med 1987; 106: 814–816.
Gaudin PB, Hruban RH, Beschorner WE, etal. Myocarditis associated with doxorubicin cardiotoxicity.Am J Clin Pathol 1993; 100: 158–163.
Ali MK, Ewer MS, Gibbs HR, Swafford J, Graff L. Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection.Cancer 1994; 74: 182–188.
Pihkala J, Saarinen UM, Lundstrom U, etal. Effects of bone marrow transplantation on myocardial function in children.Bone Marrow Transplant 1994; 13: 149–155.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carrió, I., Estorch, M. & López-Pousa, A. Assessing anthracycline cardiotoxicity in the 1990s. Eur J Nucl Med 23, 359–364 (1996). https://doi.org/10.1007/BF01247361
Issue Date:
DOI: https://doi.org/10.1007/BF01247361